Charles River Laboratories to Acquire HemaCare

Yesterday the news broke that Charles River Laboratories (NYSE:CRL) is acquiring HemaCare (OTCMKTS:HEMA) for $25.40/share in cash. I bought my first shares at the end of March and the beginning of April in 2017 for an average price of $2.53/share, just low enough to make the stock officially my first ever “ten bagger”. With that kind of performance HemaCare was obviously a driving factor behind my portfolio’s performance for the last few years, even though I did end up selling some shares along the way.

While I can’t really complain that Charles River Laboratories is not paying enough when they are paying $380 million for a business that had $35 million in revenue (ttm) and net income of $6.9 million (ttm) I’m strangely enough a little bit disappointed. In the press release Charles River Laboratories notes that they expect HemaCare to contribute at least $50 million in revenue in 2020 and to grow revenues with at least 30% for 5 years after that. It’s tough to see how that would not work out more favorable for shareholders, but of course, that is only when they do manage to achieve those goals. That’s not certain, and being part of a larger organisation is perhaps part of what will make that growth possible. And before the first rumors about a potential sale surfaced the stock was trading around $16/share, so $25.40 is more than a fair premium.

For those readers that are looking at this as a merger arbitrage, I think it’s marginally attractive. With the stock currently trading at $25.10 the spread is just 1.2%, but the merger has already received shareholder approval and is expected to close early in the first quarter of 2020. I don’t think there is anything that could realistically derail this deal, so while the spread is thin I think it’s okay. There are certainly lots of deals with smaller spreads and more risk.

Disclosure

Author is long HemaCare

8 thoughts on “Charles River Laboratories to Acquire HemaCare

  1. Braxton Gann

    Congratz!

    I hear Dan’s had a pretty nice ride as well 🙂

    I completely missed out on this one. After all, when a stock has already tripled since Dan wrote it up, how much higher can it go?

    Reply
  2. Curt

    I received this information from Rochelle Martel, HEMA Finance Director:

    “As I understand it, if you hold shares at a broker they are subject to the Dissenters Rights holding period which ends on January 22nd. After January 22nd ComputerShare will process all the shares for payment, and funds will then be transferred to the brokers and as I understand it then debited to your broker account. The process may take 3 to 5 business days subsequent to January 22nd to complete.”

    Reply
    1. Alpha Vulture Post author

      Thanks, explains why I’m still waiting for the cash. Was too be honest also quite surprised that they closed this deal so fast, actually thought they perhaps did it so that people wouldn’t have enough time to claim their dissenters rights or something. But apparently that wasn’t the case, they just wanted to get it done quickly I guess.

      Reply

Leave a Reply to Braxton Gann Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.